Aktueller stand der immuntherapie bei Alzheimer-krankheit

Translated title of the contribution: Current immune therapy for Alzheimer's disease

T. Grimmer, R. Perneczky, A. Kurz

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


New treatment strategies have developed since publication in 1991 of the amyloid hypothesis on the pathogenesis of Alzheimer's disease. In contrast to previous methods, these strategies are not for countering the effects of neuronal loss at the transmitter level. Instead, they are meant to influence the neurodegenerative process itself. They incorporate amyloid precursor protein-splitting proteases (secretase inhibitors), substances for reducing the aggregation of β-amyloid 42 (Aβ42) and stimulating specific immune reactions against it. Particularly Aβ42 and the clinical research are examined. Ethical and economic questions resulting from successful immunization against Aβ are discussed.

Translated title of the contributionCurrent immune therapy for Alzheimer's disease
Original languageGerman
Pages (from-to)832-835
Number of pages4
Issue number7
StatePublished - Jul 2008
Externally publishedYes


Dive into the research topics of 'Current immune therapy for Alzheimer's disease'. Together they form a unique fingerprint.

Cite this